Tag: Dr. Hui Zhou

Innovent Biologics’ olverembatinib gets Chinese breakthrough therapy status in SDH-deficient GIST

businessnewstoday- June 3, 2023

Innovent Biologics has been granted breakthrough therapy designation (BTD) for olverembatinib from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). ... Read More

Innovent Biologics begins parsaclisib phase 2 trial in follicular lymphoma

pharmanewsdaily- April 28, 2020

Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). ... Read More

Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies

pharmanewsdaily- November 28, 2019

Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been dosed in a phase 1 clinical trial ... Read More